Two scientists who previously worked at Orbital Therapeutics have launched ParcelBio, a new startup aiming to overcome a key technical barrier in mRNA drug development. The company announced it raised $13 million in seed funding to advance its pipeline.
The founders believe they have solved a specific problem that has limited the mRNA revolution's potential beyond vaccines. Their approach targets delivery and stability challenges that have kept many mRNA therapies from reaching patients.
The $13 million seed round will support initial research and development. ParcelBio plans to focus on therapeutic applications, though specific indications have not yet been disclosed.
The funding provides runway for early-stage work, but the company faces significant hurdles in proving its technology works in humans. The mRNA field is crowded, with established players like Moderna and BioNTech already dominating.
It remains unclear how ParcelBio's technology differs from existing approaches, and no preclinical or clinical data has been published yet.